Sander Slootweg
Managing Partner and co-founder @ Forbion Capital Partners
Almere, The Netherlands
Sander Slootweg is a Series A investor at Forbion Capital Partners in Almere focused on Biotechnology and Pharmaceutical. Sander Slootweg is based out of Bussum, North Holland and is the Managing Partner and co-founder of Forbion Capital Partners. Sander previously worked at ABN AMRO Bank as a Director. Sander Slootweg attended the VU Amsterdam.
- Total investments:
- 7
- Last investment:
- Lead investor:
- 86%
Last updated:
For AI agents: llms.txt
Industries Sander Slootweg invests in
Stages Sander Slootweg invests in
Countries Sander Slootweg invests in
Contacts
| Type | Contact | Validation |
|---|---|---|
| Work email | ||
| Personal email | ||
| Work phone | ||
| Personal phone | ||
| Socials |
Investment Focus
Industry
- Biotechnology 4 (57%)
- Pharmaceutical 3 (43%)
- Health Care 2 (29%)
- Therapeutics 2 (29%)
- Biopharma 1 (14%)
Stage
- Series A 3 (43%)
- Series B 2 (29%)
- Series C 1 (14%)
- Series D 1 (14%)
Country
- The Netherlands 3 (43%)
- United Kingdom 1 (14%)
Investments
| Company | Description | Round | Links |
|---|---|---|---|
Azafaros
|
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $147.6M / Series B / May 13, 2025 | |
NorthSea Therapeutics
|
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $80M / Series C / Dec 17, 2021 | |
New Amsterdam Pharma
|
NewAmsterdam Pharma is a clinical-stage company focused on the research and development of transformative therapies for cardio-metabolic diseases. | $194.4M / Series A / Jan 14, 2021 | |
|
Azafaros
|
Azafaros aims at developing therapeutic agents for the treatment of rare metabolic disorders such as lysosomal storage disorders through oral administration of azasugar compounds. These novel, very promising agents were discovered by Professor Hans Aerts at Leiden University and Amsterdam UMC and are exclusively licensed to Azafaros. | $27.5M / Series A / Feb 06, 2020 | |
|
NorthSea Therapeutics
|
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $39.5M / Series B / Jan 08, 2020 | |
|
NorthSea Therapeutics
|
NorthSea Therapeutics is a clinical-stage biotech company developing first-in class, oral, structurally-engineered lipid therapeutics. The team leverages Structurally Engineered Fatty Acid (SEFA) technology to develop novel and unique therapeutic approaches targeting metabolic, inflammatory and fibrotic diseases. The SEFA technology has generatedpipeline candidates with a broad array of inter- and independent biological effects, improving dyslipidemia, insulin resistance, hepatic inflammation and fibrosis in diverse models. | $26.5M / Series A / Dec 12, 2017 | |
Oxyrane UK
|
Oxyrane UK Limited is a biopharmaceutical company dedicated to the development of novel and biosuperior enzyme replacement therapies (ERT) to treat lysosomal storage diseases, a class of more than 40 rare, inherited diseases. Founded in 2006, the Company is headquartered in Manchester, United Kingdom with research facilities in Ghent, Belgium. | $26.5M / Series D / Nov 17, 2011 |
Co-Investors
About Forbion Capital Partners
Forbion Capital Partners is a Netherlands-based venture capital firm focused on investing in life sciences companies in drug development as well as MedTech companies addressing high medical needs. Forbion's investment team of nine investment professionals has built an impressive performance track record since the late nineties with successfulinvestments in Rhein Biotech, Crucell, Neutec, Glycart, Borean, Impella, Alantos, Acorda, Fovea and PanGenetics. Current assets under management exceed €400m ($500m), split between three active funds. Finally, Forbion co-manages BioGeneration Ventures, an early stage fund focused on academic spin-outs and seed investments in the Netherlands.
Forbion Capital Partners Contacts
| Name | Phone | Socials | |
|---|---|---|---|
Joy Faucher
General Partner
|
|||
Marco Boorsma
General Partner
|
|||
Nanna Lüneborg
General Partner
|
|||
Onno Stolpe
Venture Partner
|
|||
|
Sander Slootweg
Managing Partner and co-founder
|
Access 48,091 investors
822 industries, 177 countries. Updated daily. Emails and phones included.
Browse database — It's Free!
Find investors for your startup
Search 48,091 investors by industry and country. Emails and phones included.
Similar Investors
Similar stage
Recommended lists
FAQ
What does Sander Slootweg invest in?
Sander Slootweg invests primarily in Biotechnology, Pharmaceutical and Health Care startups, most often at Series A and Series B stage. Most of the 7 investments tracked by Shizune back companies in The Netherlands. The Investment Focus section breaks down every industry, stage and country in the portfolio.
How do I contact Sander Slootweg?
Public channels for Sander Slootweg include LinkedIn. For a verified work email and phone number, create a free Shizune account — contact data is searched across 20+ sources and validated before delivery, so your outreach lands in the right inbox.
When did Sander Slootweg last invest?
The most recent investment recorded for Sander Slootweg closed in May 2025. Shizune tracks 7 investments in total for this profile, including round sizes, stages and portfolio companies, all sourced from confirmed public funding rounds and refreshed monthly.
Is Shizune's investor data accurate?
Yes — every stat on this profile is calculated from confirmed public funding rounds monitored across hundreds of sources since 2020. This profile was last refreshed in Aug 2026 and is updated monthly. Spotted something off? Use the “Suggest an edit” link near the top of the page.
Contact your first 100 investors today
Find who invests in your industry, stage, and country. Download investor list with emails in 5 minutes.
Find investors — It's Free!
Continue with Google
Continue with LinkedIn
